Infratil Ltd (IFT)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 9.860 |
|---|---|
| 52-week range | 8.780 – 13.340 |
| Return, 1 month / 3 months | −15.1% / −24.4% |
| Return, 1 year / 3 years | −7.4% / +12.8% |
| Trend | Below its 200-day average |
| RSI (14) | 24 |
| Volatility (1 year) | 29.0% |
| Worst drawdown (1 year) | -25.3% |
| Average daily value traded | 3.43M AUD |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Infratil is a New Zealand infrastructure investment company based in Wellington. It invests in and manages a portfolio of businesses that provide essential services, including renewable energy generation, airport operations, healthcare and other infrastructure assets. Its investments span New Zealand, Australia and further afield, and its customers are the people and organisations that rely on those infrastructure businesses every day. Infratil takes long-term stakes in these companies and works with their management teams.
Infratil Ltd trades under the code IFT on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Infratil Ltd (IFT) trades on the Australian Securities Exchange in Australia. It last closed at AUD 9.860 on 23 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 357 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.4% and over the last three months it fell 24.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -10.9% | ||
| From 52-week high | -25.1% | ||
| Momentum | 55 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -24.4% | ||
| 6-month return | -2.4% | ||
| 12-month return, skipping the last month | 9.1% | ||
| Stability (higher is calmer) | 87 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.3% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 3.43M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 50 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −5.4% |
|---|---|
| 1 month | −15.1% |
| 3 months | −24.4% |
| 6 months | −2.4% |
| 1 year | −7.4% |
| 3 years | +12.8% |
| 5 years | +37.5% |
Signals
| 50-day / 200-day average | 11.369 / 11.065 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.290 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jun 2026 | NZD 0.0961 |
| 26 Nov 2025 | NZD 0.0598 |
| 11 Jun 2025 | NZD 0.1045 |
| 20 Nov 2024 | NZD 0.0554 |
| 29 Oct 2024 | NZD 0.0725 |
| 5 Jun 2024 | NZD 0.1090 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.